A chemotherapy drug used to fight bone-marrow cancer has the potential to treat and prevent potentially deadly heart failure, a powerful new drug-screening tool developed at UVA Health suggests.
Sep 18, 2023
0
2
A pragmatic natriuresis guided diuretic approach in patients with acute heart failure significantly increases 24-hour natriuresis without impacting all-cause mortality or heart failure rehospitalization, according to late ...
Aug 29, 2023
0
2
Active screening of patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD) more than doubles new diagnoses of cardiovascular disease compared with usual care, according to late breaking research presented ...
Aug 29, 2023
0
1
Inorganic nitrate reduces contrast-induced nephropathy (CIN), improves renal outcomes and reduces cardiac events compared to placebo in patients at risk of renal injury undergoing coronary angiography for acute coronary syndrome, ...
Aug 29, 2023
0
1
Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late breaking research presented ...
Aug 29, 2023
0
1
Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalized patients ...
Aug 29, 2023
0
1
Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable cardioverter-defibrillator (ICD) in ...
Aug 28, 2023
0
6
A new research paper titled "Cardiovascular events and death after catheter ablation in very old patients with nonvalvular atrial fibrillation" has been published inAging.
Aug 22, 2023
0
1
Patients with acute decompensated heart failure (ADHF) have significant differences according to left ventricular ejection fraction, according to a study recently published in BMC Cardiovascular Disorders.
Jul 20, 2023
0
4
A sub-study analysis of the EAST—AFNET 4 trial revealed how genetic risk for atrial fibrillation (AF) and stroke interacts with early rhythm control therapy: Early rhythm control reduces cardiovascular events in patients ...
Jun 2, 2023
0
2
